glp-1 agonists for type 2 diabetes receptor and beyond. Part 1: benefits in GLP-1 Receptor Agonists and Research
Description
As of earlier this year, 14 state Medicaid programs covered GLP-1 drugs for obesity
The growth is primarily driven by increasing awareness of diabetes and obesity, coupled with rising healthcare investments
There is also a conceptual shift underway
Cell 165, 16321643
Beyond appetite regulation: targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss
Provider model determines how you access the medication
